bismuth
compound
use
extens
medicin
particular
treatment
gastrointestin
ailment
addit
bismuth
well
known
gastroprotect
effect
efficaci
treat
h
pylori
infect
also
broad
antimicrobi
antileishmani
anticanc
properti
aspect
biolog
chemistri
bismuth
discuss
biomolecular
target
associ
bismuth
treatment
highlight
review
strive
provid
reader
date
account
bismuthbas
drug
current
use
treat
patient
discuss
potenti
medicin
applic
bismuth
drug
refer
recent
develop
literatur
ultim
review
aim
encourag
origin
contribut
excit
import
field
use
metalbas
drug
trace
back
ancient
time
rich
vari
histori
goldbas
medicin
use
china
middl
east
far
back
year
ago
mercur
chlorid
use
diuret
renaiss
period
exampl
recent
earli
twentieth
centuri
paul
ehrlich
coin
term
chemotherapi
develop
salvarsan
arsen
drug
treatment
syphili
contemporari
medicin
inorgan
chemistri
though
rel
young
vibrant
research
disciplin
mani
excel
exampl
metalbas
therapeut
diagnost
metal
chelat
inhibitor
open
access
metalloprotein
clinic
exampl
figur
develop
knowledg
role
metal
ion
biolog
system
continu
expand
ration
design
metalbas
drug
desir
care
select
metal
manipul
geometri
coordin
number
redox
state
select
appropri
ligand
lead
regul
electron
chemic
photophys
properti
individu
ligand
also
contribut
greatli
structur
divers
modul
stabil
ligand
exchang
kinet
second
coordin
sphere
interact
turn
predict
control
pharmacodynam
pharmacokinet
compound
togeth
develop
relat
metallom
provid
opportun
develop
metalbas
drug
bespok
mechan
action
bismuth
bi
known
natur
biolog
role
though
refer
bicontain
medicin
date
back
late
centuri
centuri
numer
differ
bismuth
prepar
use
treatment
varieti
disord
includ
treatment
war
wound
cholera
infantum
gastroenter
one
prepar
well
known
still
use
today
peptobismol
bismuth
subsalicyl
bss
develop
current
use
treat
gastriti
dyspepsia
current
bismuth
medic
includ
denol
colloid
bismuth
subcitr
cb
recent
develop
pylorid
ranitidin
bismuth
citrat
rbc
use
treatment
ulcer
h
pylori
infect
bismuth
thought
deriv
german
word
wismuth
white
mass
rel
rare
element
least
abund
pnictogen
group
element
claud
francoi
geoffroy
demonstr
bismuth
distinct
element
oppos
element
tin
lead
primarili
found
bismuthinit
bismuth
sulfid
bismit
bismuth
oxid
ore
sourc
byproduct
lead
copper
tin
mine
natur
monoisotop
bi
consid
heaviest
stabl
element
given
theoret
halflif
year
radioact
bi
bi
contrast
halfliv
min
respect
may
import
role
play
radiomet
radiopharmaceut
metal
charact
group
element
increas
group
bi
consid
metal
semimetal
oppos
arsen
antimoni
consid
metalloid
nitrogen
phosphor
nonmet
chemistri
arsen
antimoni
bi
certainli
less
understood
nitrogen
phosphor
bi
ground
state
electron
configur
xe
trival
pentaval
bi
bi
iii
bi
v
respect
two
predomin
oxid
state
gener
three
electron
involv
bond
format
major
compound
bi
oxid
state
compound
possess
socal
inert
pair
electron
stereochem
effect
two
electron
involv
bond
though
mani
exampl
organobismuth
v
compound
known
bi
v
halid
known
given
bi
v
strong
oxid
aqueou
solut
bi
v
bi
iii
e
v
noteworthi
bi
v
gener
stabl
biolog
solut
organobismuth
compound
least
one
direct
carbon
bi
bond
repres
import
class
organometal
compound
chemistri
organobismuth
iii
v
compound
continu
develop
mani
class
report
includ
bismuth
iii
containingheterocylc
bismacycl
heterobismacycl
triphenylbismuth
v
bi
carboxyl
complex
instanc
two
key
factor
contribut
coordin
chemistri
bi
iii
orbit
stabil
relativist
effect
result
two
electron
less
readili
avail
bond
concomit
reduct
lewi
basic
inert
pair
effect
ii
coordin
around
bi
iii
centr
particularli
bi
iii
bond
electroneg
atom
group
extend
due
signific
degre
lewi
acid
result
avail
unoccupi
andor
bix
orbit
x
halid
exampl
b
weak
shield
electron
per
lanthanid
contract
bi
iii
classifi
borderlin
lewi
acid
accord
hard
soft
acid
base
hsab
theori
therefor
form
weak
complex
hard
lewi
base
exampl
gener
though
bi
iii
known
high
affin
oxygen
nitrogen
sulphur
ligand
affin
thiolat
ligand
consid
import
properti
bi
iii
biolog
system
bi
iii
also
rel
larg
ionic
radiu
facilit
format
interest
complex
higher
coordin
number
wide
rang
geometri
regard
biolog
chemistri
bi
identif
potenti
target
bibas
drug
readili
achiev
given
develop
relat
metallom
wellestablish
though
bi
interact
nucleosidesnucleotid
ii
amino
acidspeptid
turn
iii
proteinsenzym
bismuth
exampl
demonstr
complex
nucleosid
elegantli
demonstr
crystal
structur
solv
figur
one
bi
iii
centr
centr
shown
bind
two
adenosin
via
deproton
group
second
centr
centr
bind
two
adenosin
via
deproton
group
nucleobas
adenin
via
imidazol
n
addit
bismuth
iii
complex
tpc
demonstr
bind
calf
thymu
dna
interact
though
like
noncoval
interchel
bi
iii
mention
affin
thiolat
ligand
thiolat
bi
iii
thought
major
biochem
fate
bi
iii
cell
biolog
fluid
bi
iii
readili
bind
cystein
thiolat
group
amino
acid
peptid
exampl
crystal
structur
bi
cy
solv
xray
crystallographi
demonstr
bi
iii
bind
three
cystein
thiolat
group
physiolog
ph
figur
averag
bi
bond
length
ca
furthermor
bi
iii
demonstr
bind
glutathion
gsh
tripeptid
antioxid
found
high
concentr
anim
cell
ca
mm
esim
data
indic
bi
iii
gsh
bind
ratio
previou
studi
sadler
et
al
shown
deproton
thiol
group
gsh
strongest
bind
site
bi
iii
bi
gsh
stabl
ph
rang
format
constant
bi
gsh
log
k
determin
use
hnmr
upon
titrat
gsh
bi
hedta
bi
gsh
therefor
stabl
bi
iii
complex
edta
log
k
citrat
log
k
exampl
significantli
spinecho
hnmr
experi
demonstr
rbc
react
gsh
red
blood
cell
vivo
vitro
numer
studi
bi
iii
bind
longer
peptid
sequenc
potocoki
cowork
investig
coordin
mode
thermodynam
stabil
zn
ii
cd
ii
bi
iii
ni
ii
complex
cysteinerich
ntermin
domain
fragment
zinc
transport
potentiometri
mass
spectrometri
nmr
cd
uvvi
spectroscopi
bi
iii
strongest
affin
peptid
sequenc
studi
three
cystein
thiolat
group
expect
identifi
play
key
role
bind
figur
consider
research
undertaken
relat
bi
iii
interact
protein
enzym
human
serum
transferrin
htf
metallothionein
mt
sar
coronaviru
helicas
histidin
rich
protein
hpn
heat
shock
protein
hspa
ureas
amongst
other
htf
irontransport
glycoprotein
bind
fe
iii
tightli
revers
play
key
role
iron
homeostasi
transport
fe
iii
extracellular
fluid
cytosol
found
high
concentr
blood
plasma
given
gener
ca
satur
fe
iii
bind
metal
bi
iii
ru
iii
cu
ii
ni
ii
zn
ii
yang
crystal
structur
bibound
htf
binfechtf
bi
iii
found
nlobe
per
figur
fe
iii
clobe
bi
iii
centr
bound
one
tyrosin
residu
bident
carbon
anion
synergist
anion
trident
nitrilotriacet
water
molecul
figur
bi
use
prepar
binfechtf
significantli
addit
provid
valuabl
inform
bind
mode
bi
iii
htf
structur
also
strongli
support
theori
htf
potenti
role
bibas
drug
deliveri
hydrogen
remov
clariti
colour
grey
carbon
blue
nitrogen
red
oxygen
yellow
sulphur
reproduc
permiss
copyright
american
chemic
societi
htf
backbon
shown
grey
ribbon
residu
bi
iii
repres
stick
sphere
model
respect
anomal
electron
densiti
map
contour
calcul
diffract
data
collect
shown
red
mesh
indic
locat
atom
strongli
absorb
xray
photon
energi
b
coordin
bi
iii
nlobe
binfechtf
gray
fcalc
map
contour
red
anomal
electron
map
contour
side
chain
put
bind
residu
away
bi
iii
respect
reproduc
permiss
copyright
natur
publish
group
given
histor
contemporari
contribut
bi
medicin
chemistri
togeth
interest
biolog
chemistri
reput
green
nontox
metal
much
research
undertaken
date
relat
develop
novel
bibas
drug
gastrointestin
antimicrobi
antileishmani
anticanc
agent
also
number
excel
review
book
publish
relat
chemistri
biolog
chemistri
medicin
properti
bibas
compound
though
far
exhaust
account
review
strive
provid
reader
date
insight
state
art
bi
compound
current
potenti
medicin
applic
encourag
contribut
import
field
bismuth
medic
wide
use
start
centuri
exampl
treatment
syphili
demand
declin
dramat
develop
antibiot
declin
continu
discoveri
h
pylori
bismuth
emerg
compon
effect
treatment
mani
gastrointestin
disord
efficaci
bismuth
prepar
treatment
mani
disord
attribut
number
differ
action
h
pylori
cytoprotect
effect
gastric
mucosa
h
pylori
microaerophil
neutralophil
gram
neg
bacterium
abil
colonis
human
stomach
first
identifi
potenti
pathogen
link
idiopath
gastriti
inflamm
line
stomach
marshal
warren
subsequ
h
pylori
becom
associ
dyspepsia
peptic
ulcer
gastric
cancer
recent
h
pylori
link
extragastr
diseas
cardiovascular
diseas
diabet
mellitu
sideropen
anemia
idiopath
thrombocytopen
purpura
itp
autoimmun
diseas
gallbladd
cancer
exampl
estim
percent
world
popul
infect
h
pylori
though
major
infect
peopl
develop
associ
diseas
h
pylori
develop
number
way
surviv
colonis
harsh
acid
environ
gastric
mucosa
turn
induc
chronic
infect
one
mechan
acid
acclim
wherebi
acid
environ
stomach
periplasm
ph
adjust
regul
ureas
urei
phgate
urea
channel
inner
membran
gastric
surfac
anhydras
firstlin
treatment
h
pylori
standard
tripl
therapi
drug
treatment
two
antibiot
clarithromycin
amoxicillin
tetracyclin
metronidazol
addit
proton
pump
inhibitor
ppi
significantli
h
pylori
infect
becom
increasingli
difficult
erad
due
drug
resist
associ
overus
antibiot
nonadher
treatment
regimen
bicontain
quadrupl
therapi
therefor
increasingli
recommend
firstlin
treatment
number
countri
previous
mention
clinic
use
medic
includ
bismuth
subsalicyl
pepto
bismol
bss
colloid
bismuth
subcitr
denol
cb
recent
develop
ranitidin
bismuth
citrat
pylorid
rb
mani
bibas
medicin
administ
howev
without
exact
understand
structur
behaviour
biolog
environ
inde
mechan
action
despit
medicin
use
year
exact
structur
bss
fulli
understood
andrew
cowork
though
report
import
xray
structur
provid
figur
cluster
contain
bio
core
rang
exampl
similarli
cb
also
present
challeng
regard
structur
character
mani
differ
bismuth
citrat
complex
isol
character
xray
crystallographi
given
speciat
bi
iii
citrat
complex
ph
depend
jin
et
al
solv
structur
cb
dilut
hcl
ph
use
xray
crystallographi
crystal
k
cit
reveal
presenc
three
type
bi
dinuclear
unit
bi
cit
assembl
polym
figur
c
propos
cb
may
rearrang
colloid
particl
cit
cit
neutral
ph
polym
sheet
low
ph
polymer
structur
describ
may
repres
protect
coat
found
ulcer
crater
post
treatment
channel
associ
polym
matrix
may
also
accommod
molecul
histamin
antagonist
ranitidin
wide
use
rbc
bismuth
carboxyl
compound
exampl
bss
cb
rbc
hydrolys
stomach
form
insolubl
bismuth
salt
polym
free
exert
bactericid
effect
bss
exampl
hydrolys
releas
salicyl
acid
concomit
format
bismuth
oxychlorid
gastric
juic
ph
singl
mechan
action
bactericid
activ
relat
h
pylori
yet
establish
although
experiment
evid
suggest
inhibit
enzymat
activ
ureas
may
import
ureas
dinuclear
nickel
ii
enzym
discuss
previous
play
key
role
acidacclim
facilit
bacteria
grow
highli
acid
stomach
zhang
et
al
instanc
demonstr
competit
noncompetit
inhibit
ureas
bi
iii
number
complex
includ
rbc
use
nmr
spectroscopi
sitedirect
mutagenesi
studi
suggest
bismuth
iii
bind
highli
conserv
cystein
residu
locat
entranc
ureas
activ
site
symmetri
dimer
invers
center
dimer
iiiii
dimer
w
repres
water
molecul
dimer
iiiii
l
repres
either
oxygen
water
molecul
dimer
ii
citrat
carboxyl
dimer
iii
colour
code
c
cyan
red
bi
yellow
c
project
xray
structur
k
cit
b
axi
potassium
ammonium
ion
hydrogen
atom
free
lattic
water
molecul
omit
clariti
subfigur
b
c
reprint
permiss
copyright
american
chemic
societi
bi
also
shown
high
affin
two
protein
associ
nickel
homeostasi
heat
shock
protein
hspa
h
pylori
nickel
bind
protein
hpn
interact
could
also
knockon
effect
ureas
dinuclear
ni
ii
enzym
activ
hspa
instanc
molecular
chaperon
assist
protein
fold
process
within
bacteri
cell
also
propos
involv
nickel
homeostasi
h
pylori
due
presenc
nickel
bind
domain
cy
rich
c
terminu
depend
ureas
activ
hspa
gene
bi
iii
also
report
bind
apohspa
higher
affin
nickel
ii
induc
structur
reorganis
protein
recent
propos
irrevers
bind
bi
iii
apic
domain
hspa
consist
residu
could
interfer
zinc
ii
ion
deliveri
function
associ
hspa
addit
cb
also
shown
inhibit
alcohol
dehydrogenas
adh
h
pylori
adh
produc
acetaldehyd
form
adduct
phospholipid
exogen
protein
therebi
damag
gastric
cell
caus
mucos
damag
jin
et
al
suggest
inhibit
adh
due
direct
interfer
zinc
bind
site
interact
thiol
group
bi
also
known
interact
withinhibit
fumaras
translat
factor
eftu
phospholipas
pepsin
though
exact
mechan
action
antibacteri
activ
associ
bi
yet
elucid
major
avail
evid
point
toward
bi
interact
cystein
residu
key
protein
bi
interfer
thiolcontain
metal
bind
site
variou
target
protein
h
pylori
precis
mechan
bibas
compound
heal
ulcer
also
understood
wagstaff
propos
cb
facilit
heal
lesion
form
biglycoprotein
complex
vitro
act
protect
coat
barrier
hcl
diffus
ulcer
crater
ii
stimul
prostaglandin
product
consequ
secret
alkali
mucu
layer
iii
exhibit
antibacteri
effect
h
pylori
previous
discuss
antiulc
effect
cb
may
well
complic
straightforward
precipit
ulcer
crater
though
given
known
even
though
cb
form
insolubl
precipit
acid
ph
bi
taken
gastric
intestin
mucos
tissu
bi
capabl
interact
numer
cellular
protein
studi
undoubtedli
requir
andrew
cowork
subsequ
provid
invalu
insight
possibl
structur
bss
develop
numer
famili
novel
bi
complex
excel
antih
pylori
activ
turn
made
import
contribut
topic
andrew
initi
interest
synthesi
bi
carboxyl
via
solvent
mediat
solvent
free
method
lead
develop
polymer
bi
iii
complex
reaction
acid
figur
gave
heterolept
carboxylatesulfon
complex
phbi
hsal
phbi
hsal
etoh
acid
doubli
deproton
reaction
acid
bi
oac
gave
homolept
complex
bi
hsal
acid
found
singli
doubli
deproton
molecular
structur
phbi
hsal
shown
figur
bi
centr
sixcoordin
geometri
pentagon
pyramid
sterochem
activ
lone
pair
tran
phenyl
group
found
apic
posit
ethanol
complex
phbi
hsal
etoh
determin
insolubl
aqueou
solut
wherea
two
remain
complex
remark
water
solubl
result
solut
ph
report
develop
bi
complex
water
solubl
low
ph
desir
given
link
potenti
toxic
absorpt
water
solubl
ph
bss
cb
rbc
insolubl
aqueou
solut
exampl
nonetheless
three
complex
report
mic
valu
three
laboratori
strain
h
pylori
activ
compar
favour
bss
acid
establish
acid
complex
better
activ
bss
andrew
et
al
suffici
encourag
investig
structur
chemistri
antih
pylori
activ
bi
complex
monofunct
sulfon
acid
initi
three
bisphenyl
bi
sulfon
synthes
characteris
r
ptolyl
mesityl
figur
complex
insolubl
water
aqueou
hcl
solut
molecular
structur
shown
figur
consist
polymer
helic
chain
structur
four
coordin
bi
atom
bridg
two
sulfon
atom
geometri
distort
trigon
bipyramid
complex
found
rearrang
solut
aceton
dmso
though
give
exampl
monophenyl
bi
bissulfon
bi
trissulfon
regardless
presenc
singl
sulfonato
ligand
produc
noteworthi
increas
antibacteri
activ
complex
mic
valu
compar
inact
sulfon
acid
lattic
toluen
h
atom
omit
clariti
reproduc
permiss
royal
societi
chemistri
subsequ
given
potenti
toxic
associ
releas
benzen
phenyl
bismuth
compound
andrew
cowork
concentr
develop
bi
trissulfon
four
complex
gener
formula
bi
synthes
r
phenyl
ptolyl
complex
exhibit
remark
antibacteri
activ
mic
valu
low
determin
h
pylori
strain
addit
mic
valu
found
three
complex
clinic
h
pylori
isol
significantli
lower
valu
bss
cb
rbc
correspond
complex
highlight
import
sulfon
group
relat
antibacteri
activ
class
bi
complex
interestingli
structur
produc
reaction
toluen
also
solv
figur
noteworthi
structur
describ
author
bi
iii
sulfon
oligomer
cluster
eight
bi
iii
centr
arrang
wheeltyp
structur
shield
sulfon
ligand
recent
andrew
extend
interest
bi
iii
aminoarenesulfon
complex
nine
new
trissubstitut
bi
iii
aminoarenesulfon
complex
gener
formula
bi
n
r
n
mand
paminophenyl
oaminonaphthyl
bi
complex
found
insolubl
water
aqueou
hcl
solut
also
display
notabl
vitro
activ
h
pylori
strain
investig
mic
valu
rang
mand
paminophenyl
complex
particularli
activ
clinic
h
pylori
isol
mic
valu
lower
mic
valu
previous
report
bi
trissulfon
ident
ligand
therefor
clearli
play
key
role
modul
antibacteri
effect
demonstr
incorpor
amino
function
onto
sulfon
ligand
andrew
et
al
also
develop
bi
iii
complex
nonsteroid
antiinflammatori
nsaid
report
structur
activ
bisprin
bi
iii
trisacetylsalicyl
acid
complex
acetylsalicyl
acid
aspirin
figur
ten
report
nsaid
complex
gener
formula
n
n
l
nsaid
ibuprofen
mefenam
acid
figur
b
found
exhibit
excel
vitro
activ
h
pylori
mic
valu
nmr
ftir
mass
spectrometr
data
indic
carboxyl
group
chelat
bi
iii
bident
fashion
dimer
polymer
consid
complex
exhibit
similar
vitro
activ
previous
report
bi
nsaid
complex
h
pylori
strain
investig
mic
valu
novel
bi
iii
complex
fluoroquinolon
famili
broad
spectrum
antibiot
also
possess
good
antih
pylori
activ
develop
shaikh
cowork
complex
characteris
molar
absorpt
determin
differenti
scan
calorimetri
thermogravimetr
analysi
karlfisch
aquametri
element
analysi
ftir
spectroscopi
propos
structur
bi
iii
norfloxacin
complex
shown
figur
repres
exampl
complex
develop
exhibit
better
activ
respect
fluoroquinolon
ligand
clinic
isol
strain
h
pylori
significantli
complex
also
found
activ
fluoroquinolon
resist
strain
investig
mic
valu
mgl
two
public
china
report
bi
iii
complex
glycosaminoglycan
polysaccharid
hyaluron
acid
ha
figur
natur
occur
glycosaminoglycan
consist
repeat
disaccharid
unit
nglucosamin
dglucoron
acid
highli
neg
charg
physiolog
condit
interact
readili
cation
demonstr
bind
cu
ii
ag
au
iii
fe
iii
exampl
bi
iii
complex
high
kda
medium
kda
low
molecular
weight
ha
kda
synthes
characteris
element
analysi
ftir
nmr
cd
spectroscopi
xray
diffractometri
xray
photoelectron
spectroscopi
thermogravimetr
analysi
propos
bi
iii
bind
hydroxyl
carboxyl
amino
group
ha
bi
iii
ha
complex
regardless
molecular
weight
exhibit
similar
activ
cb
mic
three
strain
h
pylori
two
novel
bi
iii
h
erinaceu
polysaccharid
hep
complex
report
recent
h
erinaceu
edibl
mushroom
wellknown
medicin
properti
bodi
h
erinaceu
use
home
remedi
treat
gastric
duoden
ulcer
amongst
diseas
two
polysaccharid
kda
isol
h
erinaceu
react
bi
give
hep
complex
characteris
element
analysi
ftir
cd
spectroscopi
sem
afm
xray
diffractometri
thermogravimetr
analysi
two
hep
shown
exhibit
modest
activ
h
pylori
strain
investig
mic
valu
bi
hep
complex
exhibit
good
activ
though
mic
valu
compar
activ
cb
studi
addit
author
highlight
bi
hep
complex
develop
lower
bi
content
cb
activ
bi
iii
ha
hep
complex
exhibit
similar
activ
cb
standard
use
studi
use
high
molecular
weight
glycosaminoglycan
polysaccharid
interest
approach
though
neither
author
specul
potenti
physiolog
impact
use
high
molecular
weight
molecul
absorpt
exampl
addit
characteris
bi
iii
complex
monoor
disaccaharid
deriv
would
sure
provid
insight
exact
natur
interact
bi
iii
carbohydr
andrew
publish
report
bi
iii
complex
artifici
sweeten
saccharin
figur
acetosulfam
cyclam
acid
increas
number
excel
public
novel
bi
iii
complex
potenti
agent
treatment
h
pylori
public
featur
complex
welldefin
fascin
vari
structur
excel
antih
pylori
activ
nonetheless
depth
mechanist
studi
turn
vivo
studi
relat
promis
compound
highli
anticip
perhap
encourag
challeng
colleagu
micromolecular
biolog
take
activ
interest
elucid
mechan
action
bibas
h
pylori
drug
summari
erad
h
pylori
import
goal
global
scientif
commun
given
associ
dyspepsia
peptic
ulcer
diseas
gastric
cancer
insight
mechan
action
bi
iii
antibacteri
effect
h
pylori
abil
heal
ulcer
certainli
better
inform
ration
develop
novel
effect
welldefin
bibas
drug
treatment
gastrointestin
disord
addit
h
pylori
bi
compound
effect
use
treat
host
bacteri
associ
infect
syphili
eg
potassium
bismuth
tartrat
bismuth
quinin
iodid
iodobismitol
coliti
bismuth
subnitr
bismuth
citrat
diarrhea
bss
bismuth
nitrat
wound
infect
bismuth
oxid
bss
exampl
wellknown
prevent
therapeut
properti
relat
diarrheal
disord
demonstr
exhibit
vitro
antibacteri
activ
enterotoxigen
e
coli
princip
bacteri
caus
diarrhea
develop
world
call
travel
diarrhea
propos
bss
capac
significantli
reduc
toxin
secretori
activ
e
coli
addit
cb
bss
activ
anoth
enteropathogen
c
difficil
cb
vitro
minimum
inhibitori
concentr
growth
bss
exhibit
noteworthi
activ
vivo
hamster
model
c
difficil
coliti
interestingli
sox
olson
report
bss
could
bind
e
coli
atcc
typhimurium
aureu
turn
bind
link
bactericid
activ
e
coli
typhimurium
though
aureu
interestingli
intracellular
atp
level
e
coli
strain
found
drop
initi
level
min
post
exposur
extracellular
atp
level
increas
rapidli
propos
exposur
bss
could
affect
membran
integr
andor
intracellular
atp
synthesi
also
noteworthi
pretreat
bss
albumin
decreas
rate
bind
kill
e
coli
ii
activ
bss
e
coli
much
rapid
ph
oppos
ph
iii
salicyl
also
possess
antibacteri
activ
therefor
may
also
contribut
activ
bss
biochem
target
bibas
compound
studi
much
extens
h
pylori
bacteria
nonetheless
reason
assum
bacteria
gener
share
key
biolog
target
bibas
compound
given
wellestablish
antibacteri
activ
bicompound
somewhat
resurg
interest
develop
novel
bibas
compound
antibacteri
agent
contrast
histor
report
relat
antifung
activ
bibas
compound
turn
limit
evid
relat
potenti
mechan
action
nonetheless
recent
report
investig
antifung
activ
bibas
compound
though
typic
accompani
antibacteri
data
consider
interest
potenti
biolog
activ
bi
iii
thiosemicarbazon
complex
thiosemicarbazon
deriv
condens
reaction
thiosemicarbazid
aldehyd
keton
rich
coordin
chemistri
report
antiparasit
antibacteri
anticanc
properti
addit
previous
demonstr
antimicrobi
activ
thiosemicarbazon
enhanc
coordin
sn
cu
ga
lessa
et
al
report
famili
bi
iii
thiosemicarbazon
bi
thiosemicarbazon
complex
potenti
antibacteri
agent
complex
develop
exhibit
good
antibacteri
activ
monoand
bi
thiosemicarbazon
bi
iii
complex
better
antibacteri
agent
correspond
free
ligand
figur
mic
tetracyclin
hydrochlorid
aureu
found
though
one
complex
test
bi
exhibit
enhanc
activ
compar
free
ligand
gramneg
bacteria
p
aeruginosa
lessa
et
al
propos
increas
solubl
bioavail
bi
coordin
key
observ
activ
number
addit
report
relat
novel
bismuth
thisosemicarbazon
complex
investig
antibacteri
agent
also
anticanc
agent
complex
featur
section
anticanc
activ
discuss
report
also
group
belo
horizont
brazil
discuss
develop
seri
bi
iii
complex
bi
benzoylhydrazon
deriv
figur
antimicrobi
activ
aureu
e
facecali
epidermidi
p
aeruginosa
c
albican
hydrazon
deriv
known
possess
antimicrobi
antitubercular
activ
though
studi
ligand
investig
found
inact
panel
microorgan
investig
contrast
gener
upon
coordin
bi
iii
antimicrobi
activ
hydrazon
deriv
enhanc
gramposit
bacteria
though
less
notabl
gramneg
bacteria
p
aeruginosa
significantli
bi
iii
complex
activ
sb
iii
analogu
bi
iii
hydrazon
complex
bi
bi
paranitrobenzoylhydrazon
found
activ
tetracyclin
aureu
xray
crystal
structur
bi
dmso
cl
figur
solv
recrystal
bi
acetonedmso
highlight
bi
iii
affin
dmso
antifung
activ
bi
iii
complex
c
albican
also
better
sb
iii
analogu
bi
iii
hydrazon
complex
bi
hacph
bi
benzoylhydrazon
mic
exhibit
better
activ
fluconazol
mic
wellknown
antifung
agent
bibas
ciprofloxacin
compound
develop
turel
cowork
ciprofloxacin
second
gener
fluoroquinolon
antibiot
develop
bibas
ciprofloxacin
compound
therefor
interest
strategi
target
antimicrobi
resisit
two
bi
iii
ciprofloxacin
cf
compound
report
cfh
cf
acid
bond
quinolon
bi
iii
observ
though
quinolon
either
singli
proton
cfh
piperazin
n
doubli
proton
carbonyl
piperazin
n
also
demonstr
similar
activ
cfhcl
viridian
enterococcu
sp
haemolyticu
g
resist
ciprofloxacin
author
appropri
discuss
potenti
impact
speciat
dissolv
compound
dmso
increas
ph
dilut
compound
media
serum
exampl
exampl
known
form
biocl
readili
aqueou
solut
bi
iii
dimethyl
sulfoxid
complex
also
potenti
form
bi
iii
complex
dissolv
dmso
evidenc
structur
figur
e
murafuji
cowork
develop
heterocycl
organobismuth
compound
antifung
agent
initi
identifi
famili
halobismuthan
deriv
diphenyl
sulfon
exhibit
promis
antifung
activ
cerevisia
interestingli
xray
crystal
structur
chlorobismuthan
figur
reveal
asymmetr
unit
contain
two
independ
molecul
differ
coordin
geometri
bi
centr
five
coordin
bi
centr
geometri
intramolecular
bio
intermolecular
bicl
interact
ii
seven
coordin
bi
centr
intramolecular
intermolecular
coordin
bio
bond
unusu
geometri
organobismuth
iii
compound
inhibitori
effect
link
lewi
acid
bi
iii
centr
propos
activ
site
subsequ
investig
effect
introduc
substitut
onto
diphenyl
sulfon
scaffold
replac
chloro
group
attach
bi
centr
undertaken
find
suggest
gener
invers
relationship
lipophil
famili
compound
antifung
activ
higher
lipophil
clogp
valu
lower
activ
halobismuthan
nonetheless
seri
organobismuth
iii
carboxyl
eg
figur
display
similar
activ
chlorobismuthan
figur
even
though
higher
clogp
valu
organobismuth
iii
dithiocarbam
analogu
figur
inact
attribut
lower
lewi
acid
due
lower
electroneg
sulphur
atom
bound
bismuth
also
high
clogp
valu
associ
compound
subsequ
studi
influenc
vari
structur
carboxyl
ligand
lipophil
antifung
activ
suggest
lipophil
carboxyl
compound
bear
antifung
activ
therefor
author
propos
organobismuth
iii
carboxyl
separ
insid
yeast
cell
cation
heterocycl
bismuth
scaffold
ionic
carboxyl
moieti
bismuth
scaffold
play
key
role
antifung
activ
bibas
compound
success
use
treat
bacteri
infect
recent
interest
area
encourag
result
surprisingli
though
fewer
report
novel
bibas
compound
potenti
antibacteri
agent
literatur
rel
metalbas
compound
gold
silver
exampl
perhap
antibacteri
properti
associ
bi
somewhat
forgotten
lack
solid
evid
relat
mechan
action
identif
concret
biomolecular
target
slow
progress
area
definit
lack
report
relat
bibas
drug
antifung
agent
littl
public
investig
possibl
antifung
mechan
action
bi
compound
accordingli
excit
opportun
challeng
exist
area
leishmaniasi
group
diseas
caus
protozoan
parasit
trypanosomatida
famili
typic
contract
bite
infect
femal
sand
fli
asia
africa
southern
europ
transmit
genu
leishmania
wherea
north
south
america
transmit
genu
phlebotomu
epidemiolog
contract
diseas
depend
strain
characterist
parasit
speci
well
contribut
factor
report
preval
countri
worldwid
million
peopl
risk
contract
diseas
million
report
leishmaniasi
estim
two
million
new
case
occur
everi
year
three
main
form
diseas
viscer
cutan
mucocutan
viscer
caus
l
donovani
l
infantumi
danger
form
diseas
treat
promptli
complet
result
death
quickli
report
case
result
death
everi
year
exampl
cutan
mucocutan
form
diseas
devast
cutan
form
ulcer
appear
site
bite
often
result
scar
wherea
mucocutan
form
partial
complet
destruct
deplet
cutan
subcutan
tissu
occur
antimoni
sb
base
drug
use
treatment
leishmaniasi
tartar
emet
potassium
antimoni
tartrat
sb
iii
compound
exampl
develop
start
centuri
initi
use
increas
surviv
rate
highli
toxic
patient
today
howev
pentaval
substitut
pentosam
sodium
stiboglucon
glucantim
meglumin
antimoni
figur
b
use
firstchoic
antileishmani
drug
mani
countri
due
lower
toxic
effici
therapeut
indic
c
overal
view
catalyt
cleft
trypanothion
reductas
tr
sb
iii
infantum
pdb
code
residu
involv
trypanothion
reduct
indic
stick
trypanothion
substrat
model
basi
cruzi
tr
structur
pdb
code
also
indic
stick
colour
cyan
reprint
permiss
copyright
american
chemic
societi
exact
mode
action
site
action
sbbase
drug
part
unknown
wide
accept
pentaval
sb
v
reduc
sb
iii
macrophag
parasit
cell
differ
thiol
includ
cystein
cystein
glycin
trypanothion
propos
biomolecular
target
includ
trypanothion
synthas
reductas
system
trypanothion
form
gluthation
specif
parasit
question
trypanothion
synthas
ts
conjug
glutathion
spermidin
form
trypanothion
glutathionyl
spermidin
trypanothion
reductas
tr
keep
molecul
reduc
form
ts
tr
system
essenti
surviv
parasit
typanosomatida
famili
reli
replac
redox
function
system
glutathion
reductas
system
present
organ
crystal
structur
reveal
sb
bind
site
tr
thu
provid
molecular
basi
antimoni
inhibit
tr
upon
reduct
tr
nadph
disulphid
bridg
associ
two
cystein
residu
separ
form
two
thiolat
group
apart
sb
iii
ion
coordin
distort
tetrahedr
geometri
two
aforement
cystein
sulphur
one
threonin
one
histidin
second
tr
form
dimer
complex
comparison
reduc
tr
sb
iii
nadph
complex
structur
trypanothion
bound
tr
l
cruzi
show
sb
iii
bind
catalyt
site
enzym
figur
sb
iii
therefor
work
prevent
interact
two
sulphur
atom
cystein
residu
act
proton
exchang
reduct
mechan
associ
glutathion
reductas
ultim
parasit
abil
buffer
oxid
stress
thought
decreas
altern
propos
explain
antileishmani
activ
sb
iii
publish
frezard
et
al
suggest
sb
iii
target
import
zinc
finger
bind
domain
respons
mani
regulatori
function
eg
dna
recognit
rna
packag
protein
fold
assembl
transcript
activ
cell
differenti
growth
apoptosi
show
sb
iii
compet
zinc
ii
bind
motif
found
leishmani
parasit
propos
competit
bind
may
respons
pharmacolog
activ
sb
drug
resist
sb
v
first
line
drug
well
contribut
factor
harsh
dosag
regimen
cardioand
hepatotox
driven
research
find
novel
drug
compound
could
use
treat
leishmaniasi
given
bi
close
proxim
period
tabl
similar
biolog
chemistri
sb
potenti
bi
drug
similar
biomolecular
target
therefor
bi
could
ideal
candid
develop
novel
metalbas
drug
field
nevertheless
import
exampl
bibas
compound
develop
evalu
potenti
antileishmani
drug
andrew
publish
extens
relat
bi
compound
activ
h
pylori
also
interest
develop
bi
compound
antileishmani
activ
activ
four
nsaid
naproxen
figur
mefenam
acid
ketoprofen
diflunis
correspond
homolept
triscarboxylato
bi
iii
complex
gener
formula
n
previous
investig
antih
pylori
activ
investig
leishmaniasi
major
promastigot
human
primari
fibroblast
cell
h
group
show
activ
highest
concentr
test
l
major
parasit
consid
high
practic
use
signific
differ
activ
naproxen
triscarboxylato
bi
iii
complex
observ
though
support
potenti
antileishmani
role
bi
bi
complex
also
toxic
toward
human
fibroblast
free
acid
also
indic
bismuth
role
human
cell
toxic
possess
lowest
structur
solv
xray
crystallographi
figur
sixcoordin
distort
pentagon
pyramid
geometri
stereochem
activ
lone
pair
found
tran
phenyl
group
found
apic
posit
test
potenti
human
toxic
fibroblast
cell
line
bi
complex
gener
significantli
toxic
free
substitut
benzoic
acid
previous
discuss
bi
nsaid
complex
andrew
cowork
recent
report
seri
bi
iii
complex
antileishmani
agent
hypothesis
bi
complex
thermodynam
stabl
bi
bond
would
less
labil
exampl
carboxyl
analogu
turn
possess
improv
hydrolyt
stabil
posit
influenc
puriti
reproduc
activ
biolog
system
though
transit
metal
pblock
metal
includ
bi
complex
report
biolog
chemistri
ligand
complex
explor
nine
differ
complex
formula
r
c
r
figur
bismuth
deriv
free
acid
test
vitro
toxic
activ
l
major
promastigot
primari
human
fibroblast
select
toxic
l
major
promastigot
oppos
primari
human
fibroblast
figur
exampl
similar
activ
antibiot
amphotericin
b
ca
parasit
kill
contrast
surprisingli
bi
iii
thioxoketon
gener
less
toxic
free
ligand
bi
complex
bi
chc
activ
seri
ca
parasit
kill
though
less
toxic
fibroblast
compar
l
major
promastigot
gener
bi
complex
display
littl
select
would
suggest
suitabl
candid
treatment
leishmaniasi
lipophil
stabil
low
labil
highlight
factor
may
import
determin
cellular
uptak
interact
biomolecular
target
two
contrast
studi
highlight
bi
antileishmani
properti
though
properti
modul
ligand
choic
well
factor
lipophil
stabil
develop
compound
select
antileishmani
activ
challeng
demich
cowork
also
interest
develop
bibas
compound
antileishmani
agent
report
sb
iii
bi
iii
complex
dipyrido
phenazin
dppz
sb
dppz
bi
dppz
figur
character
ftir
nmr
spectroscopi
element
analysi
xray
crystallographi
sb
complex
complex
along
free
ligand
dppz
test
wild
type
wt
sb
resist
sbr
strain
leishmania
infantum
chagasi
leishmania
amazonensi
associ
viscer
cutan
leishmaniasi
respect
dppz
show
intrins
activ
wt
sbr
strain
investig
vari
ca
expect
sb
iii
bi
iii
complex
show
higher
activ
strain
ca
indic
role
sb
iii
bi
iii
activ
complex
interestingli
sb
iii
bi
iii
compound
similar
activ
least
time
activ
tartar
emet
wt
sbr
strain
respect
complex
time
activ
trival
compound
wt
strain
also
interest
note
suggest
metal
alon
suffici
anti
leishmaniasi
activ
perhap
propos
improv
activ
dppz
complex
hypothesis
leishmanicid
activ
dppz
complex
may
via
dppz
intercal
parasit
dna
andor
posit
modul
lipohilicityhydrophil
dppz
complex
studi
less
lipophil
hydrophil
compound
better
activ
leishmaniasi
exampl
similar
observ
relat
lipophil
observ
andrew
recent
studi
relat
activ
gener
activ
less
lipophil
bi
iii
complex
significantli
cytotox
studi
bi
iii
sb
iii
complex
mous
periton
macrophag
mpm
show
toxic
occur
higher
level
compar
activ
concentr
leishmaniasi
promastigot
indic
potenti
select
compound
recent
studi
two
novel
triphenyl
sb
v
two
triphenyl
bi
v
complex
benzoic
acid
deriv
respect
free
ligand
screen
activ
l
amazonensi
l
infantum
promastigot
complex
type
develop
hl
acetylsalicyl
acid
aspirin
acsah
acid
characteris
ftir
nmr
spectroscopi
element
analysi
xray
crystallographi
sb
complex
propos
structur
acsa
shown
figur
per
tabl
benzoic
acid
deriv
show
activ
leishmaniasi
strain
h
treatment
novel
organo
bi
v
benzoic
acid
deriv
complex
rang
activ
correspond
sb
v
complex
rang
thought
notabl
activ
tartar
emet
rang
significantli
sb
bi
salt
least
activ
complex
fact
activ
compound
test
suggest
ligand
probabl
dissoci
complex
prior
exert
activ
tabl
inhibitori
concentr
triphenyl
sb
v
triphenyl
bi
v
complex
acetylsalicyl
acid
acid
acetylsalicyl
acid
acid
metal
salt
l
amazonensi
l
infantum
speci
promastigot
h
l
infantum
strain
l
amazonensi
strain
ic
sem
acetylsalicyl
acid
acsah
ph
sb
acsa
ph
sb
ph
sbcl
acid
ph
bi
acsa
ph
bi
ph
bico
tartar
emet
cytotox
mammalian
cell
investig
mean
mtt
assay
mous
periton
macrophag
mpm
organo
sb
v
complex
found
approxim
fold
less
toxic
organo
bi
v
complex
henc
select
leishmani
strain
studi
leishmaniasi
preval
mani
countri
worldwid
devast
diseas
one
curabl
treat
correctli
rapidli
nonetheless
resist
complianc
toxic
factor
associ
current
treatment
option
therefor
recent
interest
develop
new
bibas
drug
success
treat
leishmaniasi
bi
compound
promis
activ
report
continu
develop
evalu
novel
bi
compound
determin
bi
effect
ts
tr
system
potenti
leishmani
biomolecular
target
certainli
caus
bicompound
potenti
antileishmani
agent
cancer
major
caus
death
diseas
worldwid
accord
cancer
relat
death
predict
rise
million
past
year
platinum
compound
play
import
well
document
role
treat
cancer
spite
clinic
commerci
success
platinum
compound
wellknown
drawback
associ
use
toxic
limit
activ
resist
nonetheless
vast
amount
research
undertaken
date
relat
nonplatinumbas
compound
anticanc
agent
radiomet
asid
may
therefor
surpris
note
arsen
metal
whose
compound
approv
direct
treatment
cancer
acut
promyelocyt
leukaemia
apl
may
also
surpris
given
success
treatment
apl
lack
report
relat
develop
novel
bibas
anticanc
chemotherapeut
select
contribut
area
outlin
number
recent
public
henan
univers
kaifeng
china
contribut
stori
relat
bismuth
thisosemicarbazon
thiocarbonohydrazon
complex
anticanc
agent
structur
complex
solv
xray
crystallographi
figur
complex
account
inert
electron
pair
possess
pentagon
bipyramid
geometri
trident
monodeproton
thiosemicarbazon
ligand
one
might
expect
occupi
pentagon
plane
bi
iii
complex
nonetheless
found
significantli
less
activ
cisplatin
inde
free
ligand
leukaemia
cell
h
treatment
separ
report
later
featur
bi
iii
complex
n
pyridyl
thiosemicarbazon
hl
bi
hl
molecular
geometri
complex
account
inert
electron
pair
one
dodecahedr
neutral
thiosemicarbazon
coordin
bi
iii
via
pyridin
nitrogen
imin
nitrogen
thion
sulphur
give
two
fivememb
chelat
ring
figur
complex
exhibit
good
cytotox
panel
cancer
cell
line
leukaemia
colorect
hepatocellular
hela
cervic
cancer
cell
significantli
contrast
n
phenylthiosemicarbazon
complex
exhibit
similar
cytotox
cisplatin
superior
cytotox
free
ligand
bi
leukaemia
cell
result
annexinv
fitcpi
doubl
stain
activ
experi
cell
treat
complex
suggest
cytotox
observ
may
due
induct
apoptosi
bi
iii
centr
ninecoordin
neutral
pentadent
thiosemicarbazon
ligand
coordin
via
three
nitrogen
two
sulphur
atom
two
nitrat
ion
coordin
via
four
oxygen
atom
shown
xray
crystal
structur
figur
vitro
cytotox
complex
investig
also
leukaemia
cancer
cell
line
h
bi
iii
complex
lower
vitro
valu
free
ligand
bi
compar
previous
report
n
pyridylthiosemicarbazon
complex
figur
valu
regardless
activ
complex
investig
vivo
kunm
mice
caudal
inject
determin
mgkg
effect
xenograft
tumour
growth
inhibit
demonstr
treatment
mgkg
yank
li
et
al
develop
bi
iii
thiosemicarbazon
complex
phenylthiosemicarbazon
hl
bi
l
figur
complex
differ
substitut
pyridin
ring
pyrazin
ring
solvat
ethoxid
oppos
methoxid
n
phenylthiosemicarbazon
complex
figur
though
display
far
superior
cytotox
activ
valu
hela
cancer
cell
somewhat
similar
activ
cisplatin
cell
case
n
phenylthiosemicarbazon
complex
figur
li
et
al
provid
valuabl
insight
potenti
mechansim
action
class
compound
demonstr
phenylthiosemicarbazon
bi
iii
complex
promot
dosedepend
apoptosi
cell
associ
increas
intracellular
concentr
ro
reduct
mitochondri
membran
potenti
consider
interest
develop
bi
iii
thiosemicarbazon
complex
potenti
anticanc
antibacteri
agent
result
develop
interest
complex
good
activ
nonetheless
strategi
coordin
bi
iii
thiosemicarbazon
enhanc
activ
ligand
clearli
alway
work
therefor
develop
figur
found
cytotox
compound
studi
cytotox
free
thiocarbonohydrazon
ligand
liver
cancer
cell
author
preliminari
investig
possibl
mechan
action
complex
suggest
apoptosi
observ
connect
gener
reactiv
oxygen
speci
ro
product
also
reduct
mitochondri
membran
potenti
three
recent
public
belo
horizont
brazil
describ
novel
bi
iii
complex
cytotox
activ
de
oliveira
cowork
develop
bi
v
complex
lapachol
lp
natur
product
report
antitumour
antimalari
antileshmani
properti
properti
attribut
reactiv
oxygen
speci
gener
andor
dna
interchel
dinuclear
bi
v
complex
lp
bi
atom
bridg
one
atom
figur
found
favour
valu
compar
cisplatin
cell
significantli
bi
v
complex
also
cytotox
free
ligand
ca
report
sb
v
lapochol
complex
lp
oh
c
c
determin
stabl
aqueou
solut
rare
exampl
organobismuth
v
complex
exhibit
noteworthi
vitro
cytotox
figur
sulfapyridin
sulfonamid
antibacteri
first
synthet
antibiot
administ
clinic
longer
use
medicin
human
part
due
resist
also
potenti
risk
develop
agranulocytosi
leukopenia
nonetheless
bi
iii
complex
sulfapyridin
demonstr
inhibit
growth
leukemia
cell
h
treatment
sulfapyridin
contrast
cell
line
japan
iuchi
et
al
investig
anticanc
activ
famili
heterocycl
organobismuth
iii
compound
previous
investig
antimicrobi
agent
compound
exhibit
signific
anticanc
activ
broad
panel
cancer
cell
line
author
focus
activ
bichlorodibenzo
c
f
thiabismocin
compound
figur
human
promyelocyt
leukemia
cell
line
due
submicromolar
valu
panel
leukemia
cell
line
h
treatment
eg
ii
propens
fellow
group
compound
arsen
trioxid
effect
treat
acut
promyelocyt
leukemia
noteworthi
author
undertook
rel
comprehens
investig
mechan
action
heterocycl
organobismuth
iii
compound
compound
induc
apoptosi
low
concentr
result
internucleosom
dna
degrad
nucleu
condensationfragment
ladder
higher
concentr
acut
necrosi
observ
intracellular
atp
level
andor
ro
concentr
propos
key
factor
determin
cell
death
apoptosi
necrosi
effector
initi
intrins
mitochondri
pathway
determin
particip
observ
apoptosi
wherea
initi
extrins
death
receptor
signal
pathway
lesser
extent
iuchi
et
al
surmis
gener
ro
releas
cytochrom
mitochondria
contribut
anticanc
activ
compound
interest
articl
author
friebolin
et
al
describ
anticanc
activ
seri
xanthat
complex
bi
cu
au
ni
pd
rh
eighteen
bi
oalkyldithiocarbanato
metal
complex
synthes
total
anticanc
activ
ph
lung
breast
cancer
cell
line
investig
compar
activ
cisplatin
bi
oalkyldithiocarbanato
pt
complex
pd
complex
perform
best
follow
bi
complex
shown
figur
bi
r
isopropyl
exampl
compar
cisplatin
addit
bi
complex
also
found
activ
ph
ph
investig
given
assert
solid
tumour
often
ph
lower
carrah
jr
cowork
interest
develop
biomed
biolog
activ
group
va
metalcontain
polym
recent
exampl
work
describ
organoarsen
oraganoantimoni
oragnobismuth
polym
biolog
activ
monom
glycyrrhetin
acid
thiodiglycol
acid
norfloxacin
potenti
anticanc
agent
figur
ir
spectroscopi
hnmr
maldi
ms
employ
characteris
report
polym
ga
exampl
pentacycl
triterpenoid
medicin
properti
inhibitor
dehydrogenas
give
rise
increas
level
prostaglandin
also
potent
induc
mitochondri
permeabl
transit
therefor
trigger
proapoptot
pathway
organometal
bi
polym
ga
describ
mixtur
bridg
nonbridg
structur
bi
though
larg
nonbridg
asymmetr
characteris
consist
format
poli
ether
ester
figur
report
chain
length
organometal
bi
polym
ga
exhibit
moder
polyamin
ester
organometal
bi
polym
norfloxacin
figur
repres
better
exampl
anticanc
potenti
bi
contain
polym
norfloxacin
previous
mention
fluoroquinolon
broad
spectrum
antibiot
polym
predominantli
bridg
structur
bi
ir
spectroscopi
indic
format
bio
bin
bond
report
chain
length
bi
polym
exhibit
superior
activ
antimoni
arsenicbas
polym
four
pancreat
breast
colon
prostat
six
cancer
cell
line
test
mark
activ
pancreat
cell
line
also
superior
cisplatin
bi
polym
also
exhibit
select
cytotox
breast
cancer
cell
line
mda
compar
toxic
toward
normal
embryon
human
lung
fibroblast
cell
result
studi
encourag
anticanc
activ
bi
contain
polym
certainli
merit
investig
mani
bicontain
compound
develop
date
evalu
potenti
anticanc
agent
predominantli
develop
given
bicontain
compound
exhibit
cytotox
past
exhibit
biolog
activ
antibacteri
activ
ii
bicontain
complex
possess
ligand
previous
determin
cytotox
tent
refer
made
presenc
bi
potenti
enhanc
lipophil
particular
ligand
inde
ligand
bi
act
synergist
manner
also
noteworthi
compound
appear
exhibit
favour
cytotox
leukaemia
oppos
cancer
associ
solid
tumour
reson
activ
exampl
main
distinct
lack
inform
regard
potenti
mechan
action
bicontain
compound
anticanc
agent
though
recent
investig
strive
gain
better
understand
relat
compound
may
exert
cytotox
effect
presum
bi
iii
target
non
dna
site
turn
bicontain
compound
possess
differ
anticanc
mechan
action
compar
classic
pt
anticanc
drug
recent
elucid
pml
zinc
finger
protein
target
relat
activ
apl
provis
evid
interact
cystein
locat
zinc
finger
within
ring
domain
motif
pml
may
serv
inspir
interest
discov
relev
bi
iii
anticanc
target
grow
interest
develop
novel
bicontain
compound
anticanc
agent
extrem
posit
activ
report
compound
certainli
support
view
bicontain
drug
potenti
role
play
effect
anticanc
agent
nonetheless
ration
approach
design
compound
desir
sure
product
identif
exact
role
bi
target
cancer
prerequisit
subsequ
challeng
deliv
bi
target
must
met
whether
select
appropri
ligand
develop
bi
complex
design
bespok
organobismuth
compound
radiomet
bi
bi
also
use
develop
therapeut
radiopharmaceut
radiotherapi
use
high
energi
radiat
kill
cancer
cell
shrink
tumour
bi
bi
radionuclid
halfliv
min
respect
bi
bi
contain
radiopharmaceut
ideal
suit
treat
cancer
short
particl
rang
high
energi
deposit
use
kill
cancer
cell
damag
dna
directli
administr
dose
tumour
site
radiat
could
use
target
tumour
defect
doubl
strand
break
repair
mechan
exampl
addit
decay
ultim
stabl
isotop
offer
less
radiotox
compar
emitt
exampl
due
shorter
particl
rang
bi
thought
best
suit
though
one
daughter
radionuclid
associ
bi
tl
emit
mev
gamma
ray
number
target
bi
bibas
therapeut
radiopharmaceut
develop
even
assess
preclin
clinic
trial
involv
cancer
patient
leukemia
melanoma
glioblastoma
ideal
radiopharmaceut
high
tumour
uptak
high
tumour
background
ratio
long
resid
time
fast
renal
clearanc
target
radiopharmaceut
gener
consist
bifunct
chelat
bfc
simultan
bind
radiomet
often
via
linker
target
biomolecul
peptid
monoclon
antibodi
typic
chelat
agent
functionalis
includ
instanc
diethylenetriamin
pentaacet
acid
dtpa
figur
acid
dota
figur
song
et
al
develop
exampl
novel
bifunct
chelat
ligand
use
target
rit
bi
bi
bifunct
ligand
conjug
trastuzumab
figur
human
epiderm
growth
factor
receptor
target
antibodi
select
target
protein
overexpress
particular
cancer
includ
colorect
cancer
cherel
cowork
recent
investig
potenti
bi
radioimmunotherapi
murin
model
multipl
myeloma
specif
wish
establish
efficaci
multipl
myeloma
minim
residu
diseas
treatment
mice
low
tumour
burden
antimous
antibodi
radiolabel
bi
antibodi
modifi
cyclohexyldtpa
chelat
antigen
target
strongli
express
myeloma
cell
patient
rit
mbq
exhibit
median
surviv
greater
day
respect
compar
untreat
control
group
day
furthermor
moder
transient
toxic
associ
treatment
noteworthi
potenti
advantag
prrt
use
small
peptid
rit
lack
immunogen
fast
diffus
fast
blood
clearanc
complement
bi
halflif
min
peptid
analogu
gastrin
releas
peptid
grp
target
grp
receptor
express
invas
prostat
carcinoma
benign
prostat
tissu
high
densiti
significantli
mtd
mbq
bilabel
peptid
effect
ludotapesin
lu
emit
isotop
indic
found
better
therapi
studi
rit
prrt
bilabel
antibodi
peptid
respect
potenti
safe
effect
therapeut
approach
await
result
ongo
clinic
trial
interest
bi
may
also
number
indirect
role
play
relat
treat
cancertackl
incid
cancer
bi
link
allevi
side
effect
associ
cisplatin
treatment
exampl
nephrotox
signific
doselimit
factor
cisplatinbas
chemotherapi
administr
bi
iii
salt
prior
cisplatin
treatment
shown
depress
renal
toxic
associ
cisplatin
treatment
renoprotect
effect
thought
due
bi
increas
metallothionein
product
kidney
recent
leussink
differenti
express
gene
treat
untreat
cell
regul
gene
includ
cytochrom
c
oxidas
subunit
bar
apoptosi
regul
heatshock
protein
protein
ribosom
protein
protein
belong
translat
machineri
singl
gene
identifi
upregul
glutathion
stransferas
subunit
addit
referenc
section
link
h
pylori
gastric
cancer
second
common
caus
cancer
death
world
well
establish
h
pyloriinduc
chronic
gastriti
first
step
socal
multistep
cascad
gastric
cancer
addit
recent
h
pylori
link
extragastr
diseas
includ
gallbladd
cancer
therefor
develop
effect
bibas
treatment
h
pylori
could
turn
indirectli
posit
effect
incid
gastric
gall
bladder
cancer
worldwid
bismuthbas
drug
routin
use
treatment
gastrointestin
disord
found
key
compon
quadrupl
therapeut
regimen
becom
increasingli
common
firstlin
treatment
option
h
pylori
bismuth
also
signific
antimicrobi
antileishmani
anticanc
properti
turn
much
research
undertaken
recent
relat
synthesi
characteris
evalu
novel
bibas
compound
potenti
antimicrobi
antileishmani
anticanc
agent
significantli
mani
compound
exhibit
excel
activ
like
protein
key
biomolecular
target
bi
particularli
protein
possess
cystein
thiol
rich
domain
metal
bind
site
attract
coordin
environ
bi
metallomicmetalloproteom
approach
certainli
help
elucid
mechan
action
bi
biomolecul
ii
mechan
resist
employ
microbi
protozoan
cancer
cell
iii
mechan
biolog
uptak
storag
remov
bi
bi
bi
contain
radiopharmaceut
also
hold
much
promis
effect
anticanc
agent
radiolabel
suitabl
bifunct
chelat
ligand
bi
bi
select
effect
target
biomolecul
strategi
choic
given
notabl
resurg
interest
bioinorgan
chemistri
bi
develop
novel
class
bi
compound
consider
vari
biolog
activ
becom
increasingli
appar
bi
potenti
play
new
import
role
medicin
chemistri
